Shire
shire.comTotal trials
353
Active
4
Phase 3
149
Total enrollment
81,712
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 2 of 2 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Replagal | — | — | — | 5 | |||
| SHP611 | — | — | — | — | — | 1 |
Next readouts
- 2023-03-08
- 2026-10-31
Top conditions
- Hereditary Angioedema (HAE)26
- Healthy20
- Attention Deficit Hyperactivity Disorder (ADHD)15
- Short Bowel Syndrome15
- Ulcerative Colitis13
- Hunter Syndrome12
- Healthy Volunteers12
- Hereditary Angioedema12
Frequently asked questions about Shire
- How many clinical trials does Shire have on ClinicalTrials.gov?
- Shire is listed as the lead sponsor on 353 clinical trials in ClinicalTrials.gov, 4 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Shire's trials are in Phase 3?
- 149 of Shire's trials are in Phase 3, spread across 2 active drug programs.
- What therapeutic areas does Shire focus on?
- Shire's most-studied conditions on ClinicalTrials.gov are Hereditary Angioedema (HAE), Healthy, Attention Deficit Hyperactivity Disorder (ADHD), Short Bowel Syndrome, Ulcerative Colitis.
- When are Shire's next clinical trial readouts?
- Shire has 2 upcoming primary-completion readouts tracked here; the soonest is “A Study of Intrathecal SHP611 in Children With Metachromatic Leukodystrophy”, expected around 2023-03-08.